Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring ...

Zongertinib received FDA approval for HER2-mutant NSCLC, showing efficacy in first-line treatment with a 77% objective ...

Some 77% of patients saw their tumours shrink, 8% saw them completely disappear, and 69% saw partial shrinkage of their ...

An alliance of scientists at the Broad Institute and Bayer Pharmaceuticals have developed a drug candidate, sevabertinib, ...

In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically ...

In the histology-centric world of cancer medicine, further work is needed to increase genomic testing rates and educate ...

Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer ...

Even after Merck & Co.’s Keytruda has climbed to the top of the industry’s sales charts and racked up dozens of FDA-a | A ...

"ESMO 2025: Anticipated Phase II data debut for Eikon’s NSCLC candidate" was originally created and published by Clinical ...

Merck (MRK) stock is in focus as its blockbuster drug Keytruda as part of a combo regimen hits a secondary goal in a Phase 3 ...

FDA fast track designation for NG-350A aims to expedite its development for mismatch repair-proficient locally advanced ...

Welcome to The Pharma Letter’s real-time coverage of the 2025 European Society of Medical Oncology (ESMO) Congress, taking place October 17 to 21 in Berlin, Germany. This feed will deliver concise ...